Montreal, February 14, 2013 – Lab Bio-Medic and Algorithme Pharma are pleased to announce that they have signed a partnership agreement for the delivery of biomedical analysis required as part of clinical research projects conducted on behalf of pharmaceutical and biotech customers of this world leader in the conduct of Phase I / IIa and bioequivalence clinical trials. Under the terms of this 2 years renewable agreement, Algorithme Pharma will have a privileged access to biomedical and logistics expertise of the Lab Bio-Medic Team.
Marc Hamilton, president of Lab Bio-Medic noted:”We are honored by the decision of our partner Algorithme Pharma to select our organization as their biomedical laboratory. This is further evidence that our organization has reached a level of expertise and quality allowing us to meet the highly demanding expectations of the clinical research industry”.
According to Algorithme Pharma’s Chief Executive Officer, Chris Perkin: “We are pleased to be working with an organization that adapts and responds to the ever changing requirements of our industry including the development of software to accommodate our needs for timely clinical laboratory results”.
About Lab Bio-Medic
Part of the portfolio of Persistence Capital Partners (PCP) a private equity fund specialized in health services; Lab Bio-Medic has now two laboratories equipped with state-of-the-art equipment located in Quebec and Montreal. Since 1998, we provide routine biomedical analysis and specialized tests such as cytopathology (immunohistofluorescence test) and detection of allergies using the method of Phadia. Our services are aimed at private clinics, industrial medicine clinics, insurance companies and clinical research services. Our operations meet the requirements of the ISO-15189 certification and our technology platform is in compliance with the FDA 21 CFR part 11 of the pharmaceutical industry.
About Algorithme Pharma
As a major global player in Clinical Research and Bioanalysis, Algorithme Pharma provides a wide range of services for early stage clinical development studies to the pharmaceutical, and biotechnology industries. In addition to its multi-unit clinical facilities in Canada and the United Kingdom, Algorithme Pharma offers different services including protocol designs, CTD/ICH clinical reports, data management, biostatistics, quality assurance and regulatory affairs. Successfully audited by the US FDA, Canada TPD, Brazil ANVISA, FranceANSM, UK MHRA and Austria AGES regulatory authorities, Algorithme Pharma conducts over 200 clinical trials per year.